TMS Co

TMS Co Tangible Book Value per Share

The Tangible Book Value per Share of TMS Co (4891.T) as of Nov 4, 2026 is 60.89 JPY. In the previous year, Tangible Book Value per Share was 61.89 JPY — a change of -1.62% (lower).

Tangible Book Value per Share

60.89JPY

YoY

-1.62%

Last updated:

Tangible Book Value per Share of TMS Co is 2026 60.89 JPY. Tangible Book Value per Share of TMS Co was 2025 61.89 JPY. It decreases by -1.62% lower compared to the previous year.

The TMS Co Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2021
24.77 JPY
Jan 1, 2022
53.83 JPY
Jan 1, 2023
81.56 JPY
Jan 1, 2024
76.00 JPY
Jan 1, 2025
61.89 JPY
Jan 1, 2026
60.89 JPY
The TMS Co Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
60.89JPY-1.62%
61.89JPY-18.56%
76.00JPY-6.82%
81.56JPY+51.49%
53.83JPY+117.31%
24.77JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

TMS Co Stock analysis

What does TMS Co do? TMS Co., Ltd. generates revenue through the research and development of pharmaceutical products and medical devices, focusing on drug candidates targeting soluble epoxide hydrolase (sEH). The company develops sEH inhibitors for inflammatory diseases, with its lead candidate TMS-007 undergoing clinical development for acute cerebral infarction. TMS-007 combines anti-inflammatory and thrombolytic effects by inhibiting sEH and acting on plasminogen. The follow-on product TMS-008 is in pre-clinical studies for various inflammatory diseases. The company collaborates with academia and research institutions for R&D results, leveraging external research to advance its pipeline. TMS Co., Ltd. targets the pharmaceutical market for inflammatory disease treatments, focusing on drug candidates with dual mechanisms of action. Its primary customers are pharmaceutical companies and research institutions seeking innovative therapeutic solutions. The company's pipeline includes TMS-007 for acute cerebral infarction and TMS-008 for broader inflammatory conditions, positioning itself in the biopharmaceutical segment. The firm's revenue model relies on advancing its pipeline through clinical and pre-clinical stages, with potential partnerships for further development and commercialization. TMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TMS Co stock

Tangible Book Value per Share of TMS Co is 60.89 JPY in 2026.

Tangible Book Value per Share of TMS Co changed from 61.89 JPY to 60.89 JPY, representing a -1.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share TMS Co since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — TMS Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — TMS Co